BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 36810708)

  • 1. Comparison of MR-guided radiotherapy accumulated doses for central lung tumors with non-adaptive and online adaptive proton therapy.
    Rabe M; Palacios MA; van Sörnsen de Koste JR; Eze C; Hillbrand M; Belka C; Landry G; Senan S; Kurz C
    Med Phys; 2023 May; 50(5):2625-2636. PubMed ID: 36810708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric comparison of magnetic resonance-guided radiation therapy, intensity-modulated proton therapy and volumetric-modulated arc therapy for distal esophageal cancer.
    Barsky AR; George J; Wroe AJ; Mittauer KE; Kaiser A; Herrera R; Yu J; Gutierrez AN; Alvarez D; McCulloch J; Kasper ME; Mehta MP; Chuong MD
    Med Dosim; 2024 Summer; 49(2):121-126. PubMed ID: 38001010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different dose accumulation strategies to estimate organ doses after stereotactic magnetic resonance-guided adaptive radiotherapy.
    Regnery S; Leiner L; Buchele C; Hoegen P; Sandrini E; Held T; Deng M; Eichkorn T; Rippke C; Renkamp CK; König L; Lang K; Adeberg S; Debus J; Klüter S; Hörner-Rieber J
    Radiat Oncol; 2023 May; 18(1):92. PubMed ID: 37248504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organ sparing potential and inter-fraction robustness of adaptive intensity modulated proton therapy for lung cancer.
    van der Laan HP; Anakotta RM; Korevaar EW; Dieters M; Ubbels JF; Wijsman R; Sijtsema NM; Both S; Langendijk JA; Muijs CT; Knopf AC
    Acta Oncol; 2019 Dec; 58(12):1775-1782. PubMed ID: 31556764
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of single-energy proton pencil beam scanning Bragg peak for intensity-modulated proton therapy FLASH treatment planning in liver-hypofractionated radiation therapy.
    Wei S; Lin H; Shi C; Xiong W; Chen CC; Huang S; Press RH; Hasan S; Chhabra AM; Choi JI; Simone CB; Kang M
    Med Phys; 2022 Oct; 49(10):6560-6574. PubMed ID: 35929404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The feasibility of dose escalation using intensity-modulated radiotherapy (IMRT) and intensity-modulated proton therapy (IMPT) with FDG PET/CT guided in esophageal cancer.
    Zhang Y; Fan B; Sun T; Xu J; Yin Y; Chen Z; Zhu J; Yu J; Hu M
    J Cancer Res Ther; 2022 Sep; 18(5):1261-1267. PubMed ID: 36204871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer.
    Register SP; Zhang X; Mohan R; Chang JY
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1015-22. PubMed ID: 20615629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of grid size on uniform scanning and IMPT plans in XiO treatment planning system for brain cancer.
    Rana S; Zheng Y
    J Appl Clin Med Phys; 2015 Sep; 16(5):447–456. PubMed ID: 26699310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer.
    Liu C; Schild SE; Chang JY; Liao Z; Korte S; Shen J; Ding X; Hu Y; Kang Y; Keole SR; Sio TT; Wong WW; Sahoo N; Bues M; Liu W
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):479-489. PubMed ID: 29550033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of Adaptive MR-guided Stereotactic Body Radiotherapy (SBRT) of Lung Tumors.
    Padgett KR; Simpson GN; Llorente R; Samuels MA; Dogan N
    Cureus; 2018 Apr; 10(4):e2423. PubMed ID: 29872603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of margin reduction on radiation dose distribution of ultra-hypofractionated prostate radiotherapy utilizing a 1.5-T MR-Linac.
    Onal C; Efe E; Bozca R; Yavas C; Yavas G; Arslan G
    J Appl Clin Med Phys; 2024 Jan; 25(1):e14179. PubMed ID: 38013636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity-modulated proton and carbon-ion radiotherapy using a fixed-beam system for locally advanced lung cancer: dosimetric comparison with x-ray radiotherapy and normal tissue complication probability (NTCP) evaluation.
    Ming X; Mao J; Ma N; Chen J; Wang W; Sheng Y; Wu K
    Phys Med Biol; 2024 Jan; 69(1):. PubMed ID: 38064747
    [No Abstract]   [Full Text] [Related]  

  • 13. Dosimetric comparison of intensity modulated radiotherapy and intensity modulated proton therapy in the treatment of recurrent nasopharyngeal carcinoma.
    Hung HM; Chan OCM; Mak CH; Hung WM; Ng WT; Lee MCH
    Med Dosim; 2022 Spring; 47(1):14-19. PubMed ID: 34470708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
    Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
    Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study.
    Welsh J; Gomez D; Palmer MB; Riley BA; Mayankkumar AV; Komaki R; Dong L; Zhu XR; Likhacheva A; Liao Z; Hofstetter WL; Ajani JA; Cox JD
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1336-42. PubMed ID: 21470796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: a treament planning comparison.
    Fellin F; Azzeroni R; Maggio A; Lorentini S; Cozzarini C; Di Muzio N; Fiorino C; Calandrino R; Schwarz M
    Radiother Oncol; 2013 May; 107(2):207-12. PubMed ID: 23541644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer.
    Celik E; Baus W; Baues C; Schröder W; Clivio A; Fogliata A; Scorsetti M; Marnitz S; Cozzi L
    Radiat Oncol; 2020 May; 15(1):120. PubMed ID: 32448296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implementation of intensity modulated proton therapy for thoracic malignancies.
    Chang JY; Li H; Zhu XR; Liao Z; Zhao L; Liu A; Li Y; Sahoo N; Poenisch F; Gomez DR; Wu R; Gillin M; Zhang X
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):809-18. PubMed ID: 25260491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study.
    Zhang X; Li Y; Pan X; Xiaoqiang L; Mohan R; Komaki R; Cox JD; Chang JY
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):357-66. PubMed ID: 19660879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment plan quality during online adaptive re-planning.
    van Timmeren JE; Chamberlain M; Krayenbuehl J; Wilke L; Ehrbar S; Bogowicz M; Hartley C; Zamburlini M; Andratschke N; Garcia Schüler H; Pavic M; Balermpas P; Ryu C; Guckenberger M; Tanadini-Lang S
    Radiat Oncol; 2020 Aug; 15(1):203. PubMed ID: 32825848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.